Pharmacodynamics of natalizumab extended interval dosing in MS.
Lana Zhovtis RyersonXiaochun LiJudith D GoldbergTamara HoytAngel ChristensenRyan R MetzgerIlya KisterJohn FoleyPublished in: Neurology(R) neuroimmunology & neuroinflammation (2020)
Trough α4-integrin receptor saturation >50% correlated with high clinical efficacy of NTZ in previous studies. A continual treatment with EID maintains receptor saturation and concentration that are in the "therapeutic range" for most patients. This finding provides biological plausibility for the clinical efficacy of NTZ EID. Patients with higher BMI may require closer clinical and MRI follow-up.
Keyphrases
- multiple sclerosis
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- magnetic resonance imaging
- mass spectrometry
- peritoneal dialysis
- prognostic factors
- contrast enhanced
- patient reported outcomes
- binding protein
- magnetic resonance
- diffusion weighted imaging
- case control
- patient reported
- smoking cessation